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Embryonic stem cells (ESCs) can instruct the con-
version of differentiated cells toward pluripotency
following cell-to-cell fusion by a mechanism that is
rapid but poorly understood. Here, we used centrif-
ugal elutriation to enrich for mouse ESCs at sequen-
tial stages of the cell cycle and showed that ESCs
in S/G2 phases have an enhanced capacity to
dominantly reprogram lymphocytes and fibroblasts
in heterokaryon and hybrid assays. Reprogramming
success was associated with an ability to induce
precocious nucleotide incorporation within the
somatic partner nuclei in heterokaryons. BrdU
pulse-labeling experiments revealed that virtually all
successfully reprogrammed somatic nuclei, identi-
fied on the basis of Oct4 re-expression, had under-
gone DNA synthesis within 24 hr of fusion with
ESCs. This was essential for successful reprogram-
ming because drugs that inhibited DNA polymerase
activity effectively blocked pluripotent conversion.
These data indicate that nucleotide incorporation
is an early and critical event in the epigenetic re-
programming of somatic cells in experimental ESC-
heterokaryons.INTRODUCTION
Epigenetic reprogramming is a feature of normal embryonic
development (Feng et al., 2010) that can also be induced exper-
imentally using a range of strategies (Gurdon and Melton, 2008;
Yamanaka and Blau, 2010). For example, differentiated somatic
nuclei can regain pluripotency upon injection into oocytes
(nuclear transfer) or through the forced expression of specific
combination of transcription factors that induce a pluripotent
stem (iPS) cell state (Gurdon, 1960; Takahashi and Yamanaka,
2006). Conversion of somatic cells toward pluripotency is
associated with distinctive changes in the chromatin and DNAmethylation status of the somatic genome (Deng et al., 2009;
Simonsson and Gurdon, 2004) thought to be important for stable
re-expression of core pluripotency factors such as Oct4, Sox2,
and Nanog (reviewed by Papp and Plath, 2011). A third strategy
for reprogramming somatic cells is by cell-cell fusion. There is an
accumulating literature describing fusions between embryonic
stem cells, embryonic carcinoma (EC) and embryonic germ
(EG) cell lines with somatic cell partners such as thymocytes,
lymphocytes, fibroblasts, or hepatocytes derived from the
same or a different species (Miller and Ruddle, 1976; reviewed
by Soza-Ried and Fisher, 2012). Collectively, these experiments
have shown that somatic nuclei can be reprogrammed to acquire
the epigenetic and developmental properties of their pluripotent
partner (Ambrosi et al., 2007; Cowan et al., 2005; Do et al., 2007;
Foshay et al., 2012; Matveeva et al., 1998; Pereira et al., 2008;
Tada et al., 1997, 2001; Tat et al., 2011). Although the molecular
mechanisms that determine the success and direction (or domi-
nance) of this conversion are not fully understood, complete re-
programming is achieved 5–7 days after fusion with ESC, EG,
and EC cells and is thought to occur in two steps. First, transient
heterokaryons are formed in which both parental nuclei remain
spatially discrete but share a common cytoplasm. Low levels
of pluripotent gene expression from the somatic partner are
initiated in a proportion of heterokaryons and increase over
a 3–4 day period before the parental nuclei fuse to generate
hybrids (Pereira et al., 2008). This second step has been pro-
posed to stabilize or ‘‘fix’’ newly acquired gene expression
profiles, enabling the resulting tetraploid cells to generate plurip-
otent colonies (reviewed by Serov et al., 2011). Because the
first step occurs in the absence of cell division, it has been gener-
ally assumed that DNA synthesis is not required to initiate
reprogramming.
Although some evidence supports this view (Bhutani et al.,
2010), other studies have suggested that DNA synthesis may
be required to reverse cis-mediated silencing of genes such as
Oct4 and Nanog (Foshay et al., 2012) or have suggested that
somatic genome reprogramming occurs during the first cell
cycle (Han et al., 2008). In this regard, classic cell fusion exper-
iments performed more than 40 years ago using HeLa cells
(Rao and Johnson, 1970) had shown that early (or precocious)
DNA synthesis is induced in G1-phase cells upon fusion withCell 152, 873–883, February 14, 2013 ª2013 Elsevier Inc. 873
cells at later stages of the cell cycle (in S or G2 phases). As
DNA synthesis provides an unrivaled opportunity for chroma-
tin and nucleosome remodeling as well as changes to DNA
methylation, it is important to establish whether there is any
involvement of DNA synthesis in heterokaryon-mediated reprog-
ramming in order to understand the mechanisms behind this
conversion.
Embryonic stem cells and the pluripotent cells of the epiblast
from which they arise, have a very unusual cell-cycle structure
characterized by a short cell-cycle time, truncated G1 phase,
and a large proportion of cells in DNA synthesis (S) phase (Fluck-
iger et al., 2006; White and Dalton, 2005). Pluripotent cells in the
mouse epiblast devote more than 50% of cell-cycle time to
S phase and a similarly high proportion of mouse ESC, EG,
and EC cells (35%–50%) are reported to be in S phase (Savatier
and Afanassieff, 2002; Stead et al., 2002). This unusual profile
is associated with high levels of Cdk activity and anaphase-
promoting complex/cyclosome (APC/C) substrates present
throughout the cell cycle (Fujii-Yamamoto et al., 2005; Koledova
et al., 2010b; Yang et al., 2011). A recent report has suggested
that Cdk activity in ESCs may oscillate in a manner that is
muted as compared with differentiated or somatic cells (Balla-
beni et al., 2011). Although the biological consequences of this
unusual cell cycle are not known, evidence that ESCs loose
this profile upon differentiation (Bar-On et al., 2010; Calder
et al., 2013; Koledova et al., 2010a; Orford and Scadden,
2008) and conversely, that somatic cells regain it when reprog-
rammed (Ghule et al., 2011; Ruiz et al., 2011; Singh and Dalton,
2009), have suggested that it may be important for rapid self-
renewal of pluripotent cells.
One of the consequences of ESCs having impaired or muted
cell-cycle checkpoints is that many of the drugs that have
been traditionally used to synchronize or block somatic cells
at specific stages of the cell cycle are often either ineffective
or promote differentiation in ESCs, rendering cell-cycle studies
in undifferentiated ESCs problematic (Calegari and Huttner,
2003; Han et al., 2008; Neganova and Lako, 2008; Ruiz et al.,
2011). To circumvent this, we have optimized a biophysical
cell separation method to enrich for ESCs in discrete phases
of the cell cycle. Using this methodology we asked whether
the ability of ESCs to dominantly reprogram differentiated cells
was influenced by their cell-cycle stage. Our results show that
ESCs in late S/G2 phases of the cell cycle have a markedly
enhanced ability to reprogram somatic cells and provide evi-
dence that this is because they induce the somatic nucleus
to undergo a round of precocious DNA synthesis shortly after
fusion.
RESULTS
Cell-Cycle Synchronization of ESCs by Centrifugal
Elutriation
Counterflow centrifugal elutriation allows the separation of
heterogeneous cell populations into fractions of uniform size
and density (Banfalvi, 2008). As size and density reflect cell-cycle
stage, we used this approach to isolate mouse ESCs at sequen-
tial stages of the cell cycle from undifferentiated cultures. Briefly,
single cell suspensions of E14 ESCs were loaded into an elutria-874 Cell 152, 873–883, February 14, 2013 ª2013 Elsevier Inc.tion chamber and centrifuged at constant speed. Fractions
were collected at increasing flow rates (6–17 ml/min, F8 to
F16) and evaluated for their DNA content by staining with propi-
dium iodide (PI) followed by fluorescence-activated cell sorting
(FACS) analysis. Typical DNA content profiles of unsynchronized
ESCs and of sequential elutriated fractions are shown in Fig-
ure 1A (top and bottom panels, respectively) where the gates
used to define G1, G2, and S phase are marked. Fractions
F8 and F9 contained predominantly G1-phase ESCs (>80%),
and fraction 16 was enriched for cells in G2 (>70%), whereas
S-phase cells centered around fraction F12. The consistency
of this separation approach was confirmed in five independent
experiments (Figure S1A available online). To quantify cells
undergoing DNA synthesis within each fraction we also sub-
jected samples to a 45 min pulse of BrdU (100 mM) after elutria-
tion and then identified and scored BrdU incorporating cells
using immunofluorescence microscopy, as illustrated in Fig-
ure 1B (anti-BrdU, green). Among undifferentiated asynchronous
ESC cultures BrdU label was routinely detected in35% of cells
and the pattern of BrdU distribution within nuclei was similar to
the patterns previously reported for S-phase stages in somatic
cells (Azuara et al., 2003; McNairn and Gilbert, 2003), as shown
here for human B cells (hB) (Figure 1B and legend). In particular,
early S phase (I, II) and late S phase (IV, V) patterns were de-
tected in 42% and 20% of BrdU-labeled mouse ESCs and
characteristically marked DNA replication at either diffuse
euchromatic sites or within blocks of heterochromatin, respec-
tively. Mid-S-phase cells (III) accounted for the remaining 38%
of BrdU-labeled cells in which DNA synthesis was focused at
either perinuclear domains (a), perinucleolar sites (b) or within
dispersed sites of DAPI-intense heterochromatin (c). Using this
BrdU pulse-labeling strategy we enumerated S-phase cells
within elutriated ESC samples (Figure 1C). Fractions F11 to
F12 were enriched for S-phase cells (>60% of cells incorporated
BrdU, consistent with previous PI staining profiles). Fractions
F8 and F9 contained relatively few S-phase cells (8%–14%)
with labeling patterns indicative of early S phase (I and II). Frac-
tion F16 typically contained 20%–30% BrdU positive cells and
these cells showed a typical late S-phase distribution pattern
(IV and V).
As drug-based treatments that arrest or delay ESC cell-cycle
progression have been reported to promote differentiation and
cell death (Burdon et al., 2002; Calegari and Huttner, 2003;
Neganova and Lako, 2008; Orford and Scadden, 2008; Ruiz
et al., 2011) we asked whether elutriated ESC samples suc-
cessfully resumed cell cycle upon reculture. Fractions F8/F9,
that were relatively homogeneous and enriched for G1-phase
ESCs, were monitored for cell-cycle progression using PI stain-
ing at successive culture times (Figure 1D). G1-enriched ESC
samples (F9, day 0) progressed through to S (day 1) and G2
(day 2) phases of the cell cycle, and subsequently showed a PI
profile that resembled nonsynchronous ESC cultures (day 3).
No increase in cell differentiation or significant loss of cell viability
was detected in these cultures throughout the time course.
Furthermore, a direct comparison of cell survival in nonsyn-
chronous, G1-, S-, and G2/M-enriched ESCs cultured immedi-
ately after elutriation showed a similar viability between fractions
(Figure S1B).
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Figure 1. Separation of Mouse ESCs According to Cell-Cycle Stage Using Counterflow Centrifugal Elutriation
(A) Unsynchronizedmouse E14tg2A ESCs cells were subjected to counterflow centrifugal elutriation and sequential fractions (F8, F9, F12, F13, F16, denoting flow
rates) were stained with propidium iodide (PI) to assess DNA content by FACS. Gates used to define cells in G1, S, or G2/M are indicated in the top panel.
(B) BrdU labeling patterns that characterize successive stages of S phase in human B (hB) and mouse ESCs (mESC) are shown. Early S (I) phase is distinguished
by a fine diffuse labeling of multiple euchromatic sites that gradually increase in number and intensity by stage II. Mid S phase (III) shows BrdU incorporation at the
nuclear periphery (IIIa) and outlining nucleoli (IIIb), and in ESCs a pronounced increase in the overall number of foci (IIIc). In later stages (IV and V) large constitutive
heterochromatin domains are evident. Scale bars, 5 mm.
(C) The abundance of S-phase cells in each elutriated fraction was determined by BrdU pulse labeling (45 min, 100 mM) and anti-BrdU immunostaining.
(D) Mouse ESCs enriched for G1 using counterflow centrifugal elutriation (F9) were cultured for 1–3 days to monitor progression through the cell cycle following
elutriation. Unsynchronized ES cells are provided for comparison (in gray), and additional information is given in Figure S1.ESC Reprogramming Capacity Varies with Cell-Cycle
Stage
A previous study of hybrids generated between mouse thymo-
cytes or fibroblasts fused with mouse ESCs that had been grown
to different degrees of confluence (Sullivan et al., 2006) had
suggested that reprogramming could be optimized using stem
cells enriched for G2/M phases of the cell cycle. We used coun-
terflow centrifugal elutriation to isolate cell-cycle stages from
other variables that may occur in cultures grown to different
densities. The ability of elutriated ESC samples to stably repro-gram mouse B lymphocytes was compared using puromycin
resistant mouse B cell targets that carried a silent Oct4-GFP
transgene (GOF18DPE) (Yeom et al., 1996). These cells were
fused in a 1:1 ratio with unsynchronized or elutriated mouse
ESC fractions and the resulting cells were plated at limiting
dilution in drug-containing media for 12 days as described pre-
viously (Pereira et al., 2010) (Figure 2A). Puromycin-resistant
hybrid colonies expressing alkaline phosphatase (AP+, Puro+)
were enumerated and compared to values obtained with non-
synchronized ESCs (Figure 2B). In parallel, some colonies wereCell 152, 873–883, February 14, 2013 ª2013 Elsevier Inc. 875
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Figure 2. ESCs at Late Stages of the Cell
Cycle Are More Efficient at Reprogramming
B Cells Than Unsynchronized ESCs or G1-
Phase Cells
(A) Strategy used for generating hybrids between
mESCs (enriched in G1, S, S/G2, or G2/M)
and puromycin-resistant (Puro+) mouse B cells
(mB) derived from an Oct4-GFP transgenic line
(GOF18DPE) (Yeom et al., 1996). B cells were
predominantly in G1 (R75%), as judged by PI
staining. Successfully fused cells were plated in
media supplemented with puromycin for 21 days.
Immediately following cell fusion, the parental
mESC and mB nuclei remained discrete within
a single cell body supportedbya sharedcytoplasm
for up to 3 days. Subsequently, the nuclei fuse
giving rise to a proportion of stable proliferating
hybrid cells resistant to puromycin and positive for
alkaline phosphatase activity andOct4 expression.
(B) Reprogramming efficiency of ESCs at different
cell-cycle stages was evaluated by scoring the
number of Puro-resistant hybrid colonies positive
for AP activity (AP+). Results show the number of
AP+ colonies expressed relative to colonies ob-
tained with unsynchronized mESC (shown as 1),
where error bars represent the SD of two to three
independent experiments and asterisks denote
statistical significance (p < 0.05, t test).
(C and D) DNA methylation at the endogenous
(mCHr17) (C) and transgenic (GOF18DPE) (D)Oct4
locus in hybrid cells was assessed by bisulfite
sequence analysis, where closed circles repre-
sent methylated CpG and open circles show un-
methylated CpG. In (D) the kinetics of loss of DNA
methylation at the B cell derived transgenic Oct4
locus was monitored using a previously described
approach and primers (Han et al., 2008) and the
percentage values indicate the proportion of CpG
methylated sequences.
See also Figure S2 and Table S1.expanded to evaluate Oct4-GFP expression, DNA content, kar-
yotype, and the potential of the resulting hybrid cells to differen-
tiate. This analysis indicated that S/G2-enriched fractions of
mouse ESCs (F13) generated at least 5-fold more pluripotent
hybrid colonies than G1-enriched fractions (F8) and supported
the idea that ESCs at later stages of cell cycle have amore potent
reprogramming capacity. This enhanced reprogramming (Fig-
ure 2B; Table S1) was not a reflection of intrinsic differences in
the survival, cloning or fusion efficiency of S/G2, as shown in
control experiments (Figures S2A and S2B). Importantly, hybrid
clones generated by fusing mouse B cells with either unsyn-
chronized or G2-enriched ESC re-expressed the Oct4-GFP
transgene robustly (Figures S2C and S2D), were tetraploid (Fig-
ure S2D) and able to differentiate upon LIF withdrawal intomeso-
derm, endodermal, and ectodermal cell types (as exemplified by
clones 1,6, and 3,10, respectively; Figures S2D–S2F). Consistent
with full reprogramming of hybrid cells, a bisulfite analysis of
DNA methylation showed a near complete loss of methylated
CpG residues across endogenous mouse Oct4 alleles by day
21 (Figure 2C). To estimate when after fusion this reprogram-
ming-associated loss of DNA methylation had occurred, we876 Cell 152, 873–883, February 14, 2013 ª2013 Elsevier Inc.next performed bisulfite analysis of the promoter region of the
somatically derived Oct4-GFP transgene. This region is heavily
methylated in the parental mouse B cells (97%, Day 0) but hypo-
methylated in reprogrammed hybrids (2% methylation, day 21).
Time course experiments revealed that DNA demethylation of
the reporter was evident as early as 3 days after fusion (Fig-
ure 2D), consistent with previous studies showing that Oct4
activation is an early event required for ESC fusion-mediated
reprogramming (Han et al., 2008; Pereira et al., 2008).
Rapid and Potent Reprogramming of Human Somatic
Cells Fused with S/G2-Enriched Mouse ESCs
To explore the possible mechanisms that underlie the improved
reprogramming capacity of S/G2-enriched mouse ESCs we
performed heterokaryon analyses using human B cells or
human fibroblasts as targets (Figure 3A). This approach allows
the earliest steps in reprogramming to be followed by employ-
ing a combination of species-specific antibodies, fluorescence
in situ hybridization (FISH) probes, and RT-PCR primers to
discriminate events that occur within individual mouse and
human (somatic) nuclei after cellular fusion (Pereira et al., 2008;
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Figure 3. Mouse ESCs Enriched for S and
G2 Phases of the Cell Cycle Efficiently
Reprogram Human B Lymphocytes and
Fibroblasts in Heterokaryons
(A) Experimental strategy for generating interspe-
cies heterokaryons. Mouse ESCs (mESC) were
fused in a 1:1 ratio with human B (hB) or human
fibroblasts (hF) cells using PEG and cultured in
ESC media supplemented with puromycin.
(B) mESCs enriched according to cell-cycle stage
(G1 = F8/9, G1/S = F11/12, S/G2 = F13/14, and
G2/M = F15/16) were fused with hB cells and
hES-specific gene expressionwas assessed using
RT-qPCR and species-specific primers. Gene
expression was calculated relative to GAPDH,
using the human ESC cell line NCL1 as a positive
control (Pereira et al., 2008). Two independent
experiments are shown as examples.
(C) The potency of mESCs to induce OCT4,
NANOG, and CRIPTO expression from hB cells,
2 and 3 days after fusion was assessed in seven
independent experiments. Values were normal-
ized to G2-enriched samples, error bars denote SE
from the mean and values statistically different
from G2 (p < 0.05; single sample t test) are marked
with an asterisk.
(D) In similar experiments using human fibroblasts
as targets, humanpluripotency gene inductionwas
assessed (as above), and expression levels at day
0 (white bars) and day 4 (black bars) are shown.
Error bars denote SE from the mean of three inde-
pendent experiments, and asterisks indicate a sig-
nificant difference with a p value (t test) of < 0.05.
See also Figure S3 and Table S2.Piccolo et al., 2011). Human B cells were fused in a 1:1 ratio with
unsynchronized or G1-, S-, G2-enriched mouse ESC fractions
and expression of human pluripotency genes induced withinCell 152, 873–883,these heterokaryons was compared
using qPCR (Pereira and Fisher, 2009).
Low levels of human OCT4 (POU5F1),
NANOG, CRIPTO (Figure 3B), DNMT3b,
REX1, FGFR1, FGF2, and TLE1 (Fig-
ure S3A) transcripts were detected
2 days after fusionwithmouse ESCs (Per-
eira et al., 2010, 2008). The expression of
human pluripotency genes was consis-
tently higher in fusions performed with
S/G2 ESCs as compared with either G1
or asynchronous cells (Figures 3B and
S3B, top). This enhanced reprogramming
capacity of late S/G2 and G2-enriched
mouse ESC fractions was reproducible
and statistically significant (Figure 3C).
To determine whether somatic targets
other than lymphocytes were also sus-
ceptible, we also fused elutriated mouse
ESC fractions with human fibroblasts.
As shown in Figures 3D and S3B (lower),
reprogramming of fibroblasts was alsosignificantly enhanced following fusion with S/G2- and G2-en-
riched mESCs, as indicated by increased induction of human
OCT4, NANOG, and CRIPTO transcripts.February 14, 2013 ª2013 Elsevier Inc. 877
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Figure 4. Human Somatic Nuclei Undergo Precocious DNA Synthesis in Heterokaryons Formed with Mouse ESCs, and This Is Required for
Successful Reprogramming
(A) Confocal image of a representative heterokaryon (hB x mESC) at day 1, that was labeled for 45 min with BrdU and then stained to reveal incorporated BrdU
(green), DAPI (blue), and Phalloidin (red).
(B) Confocal Image showing simultaneous FISH detection of g-satellite probe and BrdU labeling of hB 3 mESC heterokaryons at day 1, where g-satellite (red)
selectively labelsmouse nuclei andBrdU incorporation (green) by hB nuclei is evident. The extent of BrdU incorporation by hB nuclei in heterokaryons formedwith
unsynchronized, S/G2-enriched or G1-enriched mESCs, was compared using these approaches and the results are shown in Table 1. DAPI nuclear staining is
shown in blue. Scale bars, 2 mm.
(C) Reprogramming of hB by mESCs was assayed 48 hr after heterokaryon formation in the absence (black) or presence (red) of 200 mM hydroxyurea (open
triangle), 300 mM mimosine (open square), or 2 mg/ml aphidicolin (closed circle). Values are the mean and SE of five independent experiments. Differences
between treated and untreated samples were significant with all drugs for OCT4, NANOG, and CRIPTO, and only with mimosine for DMNT3b (p value < 0.05,
t test). DNAmethylation at theOCT4 promoter was assessed 48 hr and 72 hr after fusion in the absence (black) or presence (red) of aphidicolin by HpaII digestion,
where HpaII resistant fragments were quantified by qPCR using species-specific primers (blue bar indicate position), and normalized to undigested samples.
Values shown are the mean and SD of four to six replicates in which the statistical significance is indicated by asterisks (p value < 0.005, t test).
See also Figure S4.To understand the basis of this improved reprogramming
capacity we initially examined the possibility that factors that
are known to potentiate or inhibit iPS-based reprogramming (Ya-
manaka and Blau, 2010) might fluctuate during ESC cell cycle.
We were, however, unable to detect any significant changes in
the levels of mouse Oct4, Klf4, Sox2, c-Myc, Nanog, p53, or
p21 transcripts in cell-cycle-enriched mouse ESCs (Figure S3C)
and protein levels remained unchanged for most candidates
(Figure S3D). Although western blotting and immunofluores-
cence analysis showed slight increases in Oct4 and Sox2 levels
upon cell-cycle progression (Figures S3D and S3E; Tables S2A
and S2B), careful comparison of unsynchronized and G2-en-
riched samples indicated broadly comparable levels in both (Fig-
ure S3D, red box). We did not see any experimental evidence
that these factors were either prematurely dissociated from the
chromatin or exported to the cytoplasm ahead of mitosis (Fig-
ure S3F). Likewise, Nanog expression, which displays a charac-
teristic periodicity in ESC cultures (Chambers et al., 2007) and
has been shown to enhance experimental reprogramming (Silva878 Cell 152, 873–883, February 14, 2013 ª2013 Elsevier Inc.et al., 2006; Theunissen et al., 2011), was independent on ESC
cell-cycle stage (Table S2C; Figures S3C and S3D).
S/G2 ESCs Induce Precocious Nucleotide Incorporation
in Somatic Nuclei Shortly after Fusion
An alternative explanation for the superior efficiency of S/G2-en-
riched ESCs to reprogram somatic cells is that S- or G2-phase
cells were capable of inducing premature DNA synthesis and
chromosome condensation in G1-phase targets (Johnson and
Rao, 1970; Rao and Johnson, 1970) and that this may facilitate
chromatin remodeling, DNA demethylation, and activation of
critical genes, as has been previously suggested (De Carvalho
et al., 2010; Mikkelsen et al., 2008). To examine this possibility,
we fused human B and mouse ESCs in a 1:1 ratio and after
24 hr applied a pulse of BrdU (45 min, 100 mM) to enumerate
nuclei in these cultures that were undergoing DNA synthesis.
Heterokaryons containing BrdU-labeled nuclei were then visual-
ized by DAPI (blue), phalloidin (red), and anti-BrdU (green) cos-
taining as shown in Figure 4A. Most heterokaryons contained
Table 1. Incorporation of BrdU by Human B Nuclei Contained
within 1 Day Heterokaryons Formed with Mouse ESCs
BrdU+ hB Sample Size %
Experiment 1
hB 3 unsynchronized mESC 8 24 33
hB 3 S/G2-enriched mESC 30 35 86
Experiment 2
hB 3 unsynchronized mESC 11 23 48
hB 3 S/G2-enriched mESC 14 19 74
Experiment 3
hB 3 unsynchronized mESC 10 30 33
hB 3 S/G2-enriched mESC 27 35 77
hB 3 G1-enriched mESC 0 80 <1.3
Heterokaryons between human B (hB) and mouse ESC (1:1) were
cultured for 1 day and pulse labeled with BrdU (100 mM/45 min), and re-
sulting nucleotide incorporation in hB (BrdU+hB) was assessed as shown
in Figure 4. Heterokaryons formed with S/G2-enriched mESCs contained
a higher proportion of hB nuclei that incorporated BrdU than hetero-
karyons generated with unsynchronized mESCs (p value < 0.003).BrdU-labeled nuclei (>85%) 1 day after fusion suggesting that
nucleotide incorporation was relatively common in these hetero-
karyons. The amount (intensity) and distribution of BrdU labeling
was similar to that seen in somatic and ESCs during S phase. To
discriminate human nuclei that were incorporating BrdU (BrdU+
hB, green), we used gamma satellite probe (g-satellite, red) to
selectively mark mouse nuclei (Figure 4B). Using this approach,
we scored BrdU+ hB in heterokaryons 24 hr after fusing human
B cells with either unsynchronized or G2-enriched ESCs. Data
from three independent experiments showed that a large pro-
portion of heterokaryons formed with S/G2-enriched ESCs con-
tained hB nuclei that incorporated BrdU (74%–86%, Table 1).
In heterokaryons generated with unsynchronized mouse ESCs
this proportion was lower (33%–48%). By comparison, hetero-
karyons formed with G1-enriched ESCs lacked widespread
BrdU incorporation and failed to induce DNA synthesis within
most human B cell targets (0/80, Table 1). These data show
that ESCs in S/G2 phase of cell cycle induce precocious nucle-
otide incorporation within their somatic partners during early
stages of heterokaryon formation. Consistent with this observa-
tion, ESC multikaryons that contained multiple human B cell
nuclei (as illustrated in Figure S4A) usually showed coordinated
BrdU labeling patterns in all somatic nuclei. BrdU incorporation
by somatic nuclei in heterokaryons could be detected as soon
as 5–6 hr after fusion with a pattern that was typical of early
S phase (Figure S4B). Importantly, BrdU labeling was not seen
in most hB homokaryons (Figure S4C) or within human B cells
that had been engulfed by mouse ESCs but had retained a
discrete cell wall (Figure S4D). This suggests that precocious
DNA synthesis in lymphocyte nuclei is an early feature induced
by ESC that requires the establishment of a shared cytoplasm.
To determine whether nucleotide incorporation by somatic
nuclei was likely to reflect widespread DNA repair or genuine
DNA replication, we performed DNA FISH analysis and scored
doublet FISH signals 24 hr after fusion. Using genomic probes
for human a-globin and b-globin (loci that replicate early andlate in B cells, respectively) (Brown et al., 2001) together with
EdU (to visualize nucleotide incorporation), we routinely de-
tected doublet signals for a-globin in human B nuclei 24 hr after
fusion (24/25 nuclei, 98%), whereas b-globin appeared as singlet
signals (exemplified in the mid-S-phase nucleus shown in Fig-
ure S4E). As doublets reflect the separation of newly replicated
sister chromatids during S phase (Azuara et al., 2003; Selig
et al., 1992) these data are consistent with human somatic nuclei
undergoing DNA replication. Parallel experiments using human
fibroblasts (IMR90, hF) showed widespread BrdU incorporation
by somatic nuclei a day after fusion with unsynchronized ESCs
(Figure S4F), with doublet FISH signals (HUWE1) clearly evident
at days 2–3 (Figure S4G). These data confirmed human DNA
replication in ESC-heterokaryons ahead of nuclear fusion.
DNA Replication Is Critical for Initiating Successful
Reprogramming of Somatic Nuclei toward Pluripotency
in ESC-Derived Heterokaryons
To evaluate whether DNA synthesis was required to initiate
pluripotent gene expression from somatic nuclei, we fused
human B cells and mouse ESCs and then monitored human
pluripotent gene induction following treatment with agents that
block DNA synthesis. Treatment of heterokaryons with aphidico-
lin (a drug that inhibits DNA polymerase activity), mimosine (that
arrests cells in late G1) or with hydroxyurea (to prevent late origin
firing) for 48 hr severely compromised the induction of a panel
of human pluripotency genes as compared with untreated con-
trols (Figure 4C, top). DNA demethylation at endogenous human
OCT4 alleles was evident in untreated cultures, as indicated
by increased sensitivity to HpaII digestion (Figure 4C, bottom,
black). However, in parallel cultures in which DNA polymerase
activity was inhibited by aphidicolin treatment, we detected
no corresponding change in sensitivity of the OCT4 locus (Fig-
ure 4C, bottom, red). Taken together, these data suggested
that precocious DNA synthesis within somatic nuclei was critical
for remodeling and demethylating the humanOCT4 locus prior to
its reactivation in heterokaryons.
Oct4 Re-Expression and Precocious DNA Synthesis
The incidence of precocious DNA synthesis among success-
fully reprogrammed ESC heterokaryons was evaluated in BrdU
tracing experiments, using Oct4-GFP as a reporter. Briefly,
mouse B cells carryingOct4-GFPwere fused with nonsynchron-
ized ESCs and pulse labeled with BrdU (100 mM, 45 min) at
different times early after fusion (at 6, 18, or 24 hr, or double-
pulsed at 6 and 18 hr), washed and returned to culture. Two
to 3 days after fusion heterokaryons that contained ‘‘reprog-
rammed lymphocytes’’ were identified on the basis of GFP re-
expression and then examined to ask whether these cells
retained BrdU that had been acquired during the time window
of the pulse. A schematic representation of this experiment is
depicted in Figure 5A. As shown in Figure 5B and illustrated in
Figure 5C, most Oct4-GFP positive heterokaryons (green) iden-
tified 2-3 days after fusion had incorporated BrdU (red) within
the first few hours of fusion. Specifically, we demonstrated that
about a third of all successfully reprogrammed cells were
marked by BrdU applied 6 hr postfusion and about two thirds
of all successfully reprogrammed cells were marked by BrdUCell 152, 873–883, February 14, 2013 ª2013 Elsevier Inc. 879
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Figure 5. Somatic Nuclei that Re-Express
Oct4 ShowWidespread Nucleotide Incorpo-
ration within 24 hr of Heterokaryon Forma-
tion with ESCs
(A) Experimental strategy used to assess the
kinetics of BrdU incorporation in successfully re-
programmed mB cells. Heterokaryons formed
between mouse ESCs and B cells were pulse
labeled (45 min) with BrdU at different times points
after fusion (6, 18, or 24 hr) in separate experi-
ments or pulse labeled twice at 6 and 18 hr after
fusion in a single experiment. BrdU incorporation
was analyzed among successful reprogrammed
mouse B cells identified on the basis of Oct4-GFP
re-expression at 2–3 days after fusion.
(B) Reprogrammed cells (33%–37%) had already
incorporated BrdU during a pulse labeling applied
6 hr after fusion, a percentage that increased to
62% and 76%when fused cells were pulse labeled
at 18 and 24 hr, respectively. Sequential pulse
labeling at 6 and 18 hr demonstrates that the
majority of successfully reprogrammed hetero-
karyons (90%) incorporated BrdU within a day of
fusion.
(C) Confocal image of a successfully repro-
grammed mouse B cell (mB, arrow) identified on
the basis of Oct4-GFP (green) re-expression at
48 hr, that had incorporated BrdU (red) during
a pulse applied 6 hr after PEG-mediated fusion
with mESCs (mESC, arrow). Scale bar, 5 mm.applied 18 hr postfusion. By applying a double pulse of BrdU at
6 and 18 hr after fusion, virtually all (90%) successfully reprog-
rammed B cells identified on the basis of Oct4 re-expression,
were shown to have undergone DNA synthesis within a day of
fusion with ESCs.
DISCUSSION
Here we provide quantitative evidence that dominant reprog-
ramming of somatic cells by ESCs is enhanced using S/G2-en-
riched samples. This extends claims made from hybrid studies
(Sullivan et al., 2006) showing that the potency of S/G2 ESCs
occurs in heterokaryons when pluripotent gene expression is
initiated. We found no evidence that the improved reprogram-
ming efficiency of S/G2 ESCswas due to reprogramming factors
present in cells at later stages of the cell cycle or their ‘‘release’’
into the cytoplasm prior to mitotic chromosome condensation.
Rather, our data indicate that ESCs in S/G2 induce B cells or
fibroblasts to undergo DNA synthesis within a day of fusion
and heterokaryon formation. This is important for reprogram-
ming as inhibitors of DNA synthesis such as hydroxyurea, mim-
osine and aphidicolin, blocked pluripotent gene induction in
heterokaryons. We also found that virtually all heterokaryons
that re-expressed a somatically derived Oct4-GFP transgene
showed evidence of premature DNA synthesis occurring within
the first day after fusion. Collectively, this indicates that early
DNA synthesis is a critical feature of successful stem cell
fusion-mediated reprogramming that has not been fully appreci-
ated until now.
Interestingly, reprogramming studies using nuclear transfer
have indicated that cell-cycle synchronization between the880 Cell 152, 873–883, February 14, 2013 ª2013 Elsevier Inc.donor nucleus and recipient cytoplasm appears to be important
(Campbell and Alberio, 2003; Campbell et al., 1996) and the
ability of mammalian embryonic cytoplasm to support reprog-
ramming has been shown to fluctuate with the cell cycle (Egli
et al., 2007). Although synchronization of the cell cycle is not
sufficient to determine successful reprogramming in hetero-
karyons per se (i.e., G1-phase ESCs do not efficiently reprogram
G1-phase B cells), our data may highlight the importance of
cell-cycle ‘‘compatibility’’ between nuclei inducing and nuclei
undergoing reprogramming. Consistent with classical studies
of cell-cycle progression (Blow and Laskey, 1988) and the cell
fusion experiments reported by Johnson and Rao (1970) and
Rao and Johnson (1970), we showed that fusing S/G2-phase
ESCs with somatic cells induced precocious DNA synthesis in
somatic nuclei. As 70%–75% of cultured human B cells are in
G1, most of these targets would be expected to be already
licensed for DNA replication (reviewed in Blow and Dutta,
2005) and therefore susceptible to S-phase promotion by S/G2
ESCs. In this regard, recent experiments using Xenopus egg
extracts at the metaphase (M phase) stage have also shown
that M phase can both drive DNA synthesis and improve reprog-
ramming efficiency in nuclear transfer and in iPS assays (Ganier
et al., 2011). iPS-based studies have, in addition, indicated that
reprogramming can be accelerated by DNA synthesis and cell
division (Hanna et al., 2009) as well as by agents that inhibit
histone deacetylation (Huangfu et al., 2008) or interfere with
the maintenance of DNA methylation (De Carvalho et al., 2010;
Feng et al., 2009; Mikkelsen et al., 2008).
The demonstration that nucleotide incorporation is wide-
spread among somatic nuclei in heterokaryons raises the
possibility that DNA demethylation of genes that are critical
for reprogramming, such as Oct4 (Simonsson and Gurdon,
2004) could be achieved by replication-dependent (passive)
means. Previous studies have implicated AID-mediated deami-
nation in active DNA demethylation in heterokaryons (Bhutani
et al., 2010), and Gadd45 (growth arrest and DNA damage 45
protein) in active DNA demethylation during differentiation and
stress response (Niehrs and Scha¨fer, 2012). In preimplantation
embryos, both active and passive mechanisms have been
implicated in genome-wide DNA demethylation in which Tet3-
mediated conversion of 5-methylcytosine to 5-hydroxy-methyl-
cytosine appears to be central (Gu et al., 2011; Inoue and Zhang,
2011). In ESCs, Tet1 and Tet2 family members are actively ex-
pressed (Ficz et al., 2011; Wu and Zhang, 2011; Xu et al.,
2011) and recent studies have implicated Tet2 and Parp1 in
iPS-based reprogramming (Doege et al., 2012). In an accompa-
nying manuscript (Piccolo et al., 2013) we show that Tet1 and
Tet2 participate in ESC- and EG-mediated heterokaryon reprog-
ramming and are required to reset DNA methylation within the
somatic genome. Interestingly, as conversion of 5-methylcyto-
sine to 5-hydroxy-methylcytosine can occur in the presence
of drugs that inhibit DNA replication (Piccolo et al., 2013), it
seems likely that both active (DNA replication-independent)
and passive (DNA replication-dependent) mechanismsmay con-
tribute to pluripotent reprogramming in ESC heterokaryons. This
duality may be helpful in reconciling some of the conflicting data
arising from reprogramming studies in vivo, as well as providing
an explanation for the recent proposal that heterokaryon-medi-
ated reprogramming is mechanistically biphasic (Foshay et al.,
2012).
The observation that early DNA synthesis is prevalent in
somatic nuclei fused with ESCs is however at odds with a
previous report in which BrdU incorporation was not seen in
heterokaryons formed between human fibroblasts and mouse
ESCs (Bhutani et al., 2010). Although we do not at present
have an explanation for this, it is unlikely that this discrepancy
is due to the use of different somatic cells or to interspecies
incompatibilities as we observed extensive BrdU incorporation
using both human and mouse fibroblasts. In our hands AID
expression (a putative mediator of 5-methylcytosine deamina-
tion) was not detectable in fused or unfused cells, as has
been reported by others (Foshay et al., 2012). Regardless of
the explanation for these differences, our study offers a fresh
perspective on how reprogramming works as well as providing
a simple and reliable method for enriching ESCs at different
cell-cycle stages. This will be important for future reprogram-
ming studies and to better understand the importance of
the unusual cell-cycle structure in pluripotent stem cell self-
renewal.
EXPERIMENTAL PROCEDURES
Cell Culture
E14Tg2a Hprt/ (E14) mouse ESCs, EBV-transformed human B cells, and
Abelson-transformed mouse B cells were cultured as described previously
(Pereira et al., 2008).
Quantitative RT-PCR Analysis
RNA extraction and RT-qPCRwas carried out as described previously (Pereira
et al., 2008; primer sequences shown in Table S1).Centrifugal Elutriation
Counter-flow centrifugal elutriation was carried out using JE-5.0 elutriator
system (Beckman Coulter) in combination with MasterFlex peristaltic pump
(Cole-Parmer Instrument) as described by Banfalvi (2008) and detailed in
Extended Experimental Procedures.
Heterokaryons and Hybrid Assays
Heterokaryonswere generatedby fusingmouseESCs enriched at different cell-
cycle stages and human B cells (mESC/hB ratio 1:1) using polyethylene glycol
(PEG) as described previously (Pereira and Fisher, 2009). Nonfused mouse
ESCswere eliminatedbysupplementing themediumwithHAT (20mMhypoxan-
thine,0.08mMaminopterin, and3.2mMthymidine;Sigma)orPuromycin (1mg/ml;
Sigma). Nonfused hB cells were, where appropriate, eliminated using ouabain
(105M; Sigma) applied at least 6–18 hr after cell fusion, and details of immuno-
fluorescence analyses are provided in Extended Experimental Procedures.
Hybrids between mESCs (enriched either in G1, S, S/G2, or G2/M) and
puromycin-resistant (Puro+) mB cells were generated by PEG-mediated fusion
(mESC/mB ratio 1:1) (Pereira and Fisher, 2009). Nonfused mESCs were elim-
inated by the addition of Puromycin (1 mg/ml; Sigma), and alkaline phospha-
tase staining was performed on colonies 12 days after fusion.
Protein Extraction and Western Blot Analysis
Whole-cell protein extracts were prepared with Laemmli buffer, and nuclear
and cytoplasmic protein extracts were prepared as described in Extended
Experimental Procedures. Western blot analysis were performed using the
following antibodies: goat polyclonal to Oct4 (1:2,000; sc-8628, Santa Cruz
Biotechnology), Sox2 (1:2,000; sc-17320, Santa Cruz Biotechnology), and
LaminB (1:5,000; sc-6216, Santa Cruz Biotechnology); Mouse monoclonal
to c-Myc (9E10) (1:2000; sc-40, Santa Cruz Biotechnology) and Tubulin
(1:2,000; T9026 Sigma-Aldrich); rabbit polyclonal to CTCF (1:500; ab70303
Abcam). The secondary antibodies used were anti-mouse HRP (1:2000, GE
Healthcare), anti-rabbit HRP (1:5,000, GE Healthcare), and anti-goat HRP
(1:2000, sc-2020 Santa Cruz Biotechnology). The Amersham ECL plus kit
(GE Healthcare) was used for detection.
Immunofluorescence, FISH, and BrdU detection
Immunofluorescence analysis was performed (Terranova et al., 2006) using
goat polyclonal to Oct4 (1:200, sc-8628, Santa Cruz Biotechnology) and
Sox2 (1:200, sc-17320, Santa Cruz Biotechnology), and secondary antibodies
at 1:400 dilution (Molecular Probes). BrdU incorporation and detection was
performed in low light conditions as described by Azuara et al. (2003) where
heterokaryons were grown on gelatinized coverslips for 1 day, pulse labeled
with 100 mM BrdU added to the media for 45 min, and fixed with 2% parafor-
maldehyde in PBS for 20 min at room temperature. Blocking and washing was
performed as described by Terranova et al. (2006). Phalloidin-Alexa Fluor 568
(Invitrogen A12380, diluted 1:50 in blocking buffer) and/or BrdU-FITC (Becton-
Dickinson 347583, diluted 1:4 in blocking buffer) were applied for 30 min
before final washes and mounting in Vector-shield containing 0.5 mg/ml
DAPI (Sigma D9542). Three-dimensional DNA FISH for human a- and b-globin
were performed as described (Brown et al., 2001) on heterokaryons growing
on 0.2% gelatin-coated coverslips. To codetect EdU incorporated as a
45 min pulse label before cell fixation, the Click-iT kit (Invitrogen) was used
according to manufacturer’s instructions following the sodium borohydride
step. Coverslips were subsequently washed with PBS, blocked as described
in the 3D FISH protocol before postfixation and DNA denaturation, and kept in
the dark following detection of EdU.
Bisulfite Sequencing Analysis
Bisulfite treatment of genomic DNA was performed with the EZDNA methyla-
tion kit (Zymogenetics). Bisulfite-converted DNA was used as template to
amplify endogenous (Oct4) and transgenic Oct4 (GOF18DPE) (tOct4) (primers
are available in Extended Experimental Procedures). PCR products were
cloned into pCR2 vector (Invitrogen) and randomly sequenced.
HpaII Resistance Assay
Genomic DNA (5 mg/sample) was digested with HpaII (50 U, NEB), with MspI
(100 U, NEB), or left untreated (undigested) for 4 hr at 37C, followed byCell 152, 873–883, February 14, 2013 ª2013 Elsevier Inc. 881
proteinase K treatment (30min at 40C). HpaII-resistance was quantified using
qPCR and primers that flanked an HpaII/MspI-sensitive site in the promoter
region of OCT4. Ct values were normalized to a region lacking an HpaII/
MspI site and to untreated controls. HpaII resistance was calculated as the
percentage difference between HpaII (test) and MspI (total) digested samples.
Primers are available in Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and two tables and can be found with this article online at http://dx.
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